198 related articles for article (PubMed ID: 10520053)
21. The Impact on Allergy-Related Cells of a Birch Pollen Allergoid, with and without Monophosphoryl Lipid A, in Comparison with the Native Equivalent.
Worm M; Ernst D; Kraller M; Babina M
Int Arch Allergy Immunol; 2017; 172(1):20-26. PubMed ID: 28219062
[TBL] [Abstract][Full Text] [Related]
22. Tree-pollen allergy is efficiently treated by short-term immunotherapy (STI) with seven preseasonal injections of molecular standardized allergens.
Balda BR; Wolf H; Baumgarten C; Klimek L; Rasp G; Kunkel G; Müller S; Mann W; Hauswald B; Heppt W; Przybilla B; Amon U; Bischoff R; Becher G; Hummel S; Frosch PJ; Rustemeyer T; Jäger L; Brehler R; Luger T; Schnitker J
Allergy; 1998 Aug; 53(8):740-8. PubMed ID: 9722222
[TBL] [Abstract][Full Text] [Related]
23. Local nasal immunotherapy for birch allergic rhinitis with extract in powder form.
Andri L; Senna G; Andri G; Dama A; Givanni S; Betteli C; Dimitri G; Falagiani P; Mezzelani P
Clin Exp Allergy; 1995 Nov; 25(11):1092-9. PubMed ID: 8581842
[TBL] [Abstract][Full Text] [Related]
24. Effect of sublingual immunotherapy with grass monomeric allergoid on allergen-specific T-cell proliferation and interleukin 10 production.
Burastero SE; Mistrello G; Falagiani P; Paolucci C; Breda D; Roncarolo D; Zanotta S; Monasterolo G; Rossi RE
Ann Allergy Asthma Immunol; 2008 Apr; 100(4):343-50. PubMed ID: 18450120
[TBL] [Abstract][Full Text] [Related]
25. Oligoclonal analysis of the atopic T cell response to the group 1 allergen of Cynodon dactylon (bermuda grass) pollen: pre- and post-allergen-specific immunotherapy.
Eusebius NP; Papalia L; Suphioglu C; McLellan SC; Varney M; Rolland JM; O'Hehir RE
Int Arch Allergy Immunol; 2002 Mar; 127(3):234-44. PubMed ID: 11979049
[TBL] [Abstract][Full Text] [Related]
26. Accelerated Up-Dosing of Subcutaneous Immunotherapy with a Registered Allergoid Birch Pollen Preparation.
Buczyłko K; van der Werf JF; Boot D; van Ree R
Int Arch Allergy Immunol; 2017; 172(3):183-186. PubMed ID: 28380494
[TBL] [Abstract][Full Text] [Related]
27. Allergen-specific CD4+ T cell responses in peripheral blood do not predict the early onset of clinical efficacy during grass pollen sublingual immunotherapy.
Bonvalet M; Moussu H; Wambre E; Ricarte C; Horiot S; Rimaniol AC; Kwok WW; Horak F; de Beaumont O; Baron-Bodo V; Moingeon P
Clin Exp Allergy; 2012 Dec; 42(12):1745-55. PubMed ID: 23181790
[TBL] [Abstract][Full Text] [Related]
28. Birch pollen immunotherapy leads to differential induction of regulatory T cells and delayed helper T cell immune deviation.
Möbs C; Slotosch C; Löffler H; Jakob T; Hertl M; Pfützner W
J Immunol; 2010 Feb; 184(4):2194-203. PubMed ID: 20048125
[TBL] [Abstract][Full Text] [Related]
29. Short-term immunotherapy: a prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis.
Zenner HP; Baumgarten C; Rasp G; Fuchs T; Kunkel G; Hauswald B; Ring J; Effendy I; Behrendt W; Frosch PJ; Przybilla B; Brunner FX; Merk HF; Kapp A; Schnitker J; Wolf H
J Allergy Clin Immunol; 1997 Jul; 100(1):23-9. PubMed ID: 9257783
[TBL] [Abstract][Full Text] [Related]
30. Effect of anti-immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitis.
Bez C; Schubert R; Kopp M; Ersfeld Y; Rosewich M; Kuehr J; Kamin W; Berg AV; Wahu U; Zielen S
Clin Exp Allergy; 2004 Jul; 34(7):1079-85. PubMed ID: 15248853
[TBL] [Abstract][Full Text] [Related]
31. Pollen derived low molecular compounds enhance the human allergen specific immune response in vivo.
Gilles-Stein S; Beck I; Chaker A; Bas M; McIntyre M; Cifuentes L; Petersen A; Gutermuth J; Schmidt-Weber C; Behrendt H; Traidl-Hoffmann C
Clin Exp Allergy; 2016 Oct; 46(10):1355-65. PubMed ID: 27061126
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy with sublingual birch pollen extract. A short-term double-blind placebo study.
Horak F; Stübner P; Berger UE; Marks B; Toth J; Jäger S
J Investig Allergol Clin Immunol; 1998; 8(3):165-71. PubMed ID: 9684190
[TBL] [Abstract][Full Text] [Related]
33. Grass pollen immunotherapy: symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season.
Wilson DR; Nouri-Aria KT; Walker SM; Pajno GB; O'Brien F; Jacobson MR; Mackay IS; Durham SR
J Allergy Clin Immunol; 2001 Jun; 107(6):971-6. PubMed ID: 11398073
[TBL] [Abstract][Full Text] [Related]
34. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity.
Nouri-Aria KT; Wachholz PA; Francis JN; Jacobson MR; Walker SM; Wilcock LK; Staple SQ; Aalberse RC; Till SJ; Durham SR
J Immunol; 2004 Mar; 172(5):3252-9. PubMed ID: 14978133
[TBL] [Abstract][Full Text] [Related]
35. Comparison of nasal immunohistology in patients with seasonal rhinoconjunctivitis treated with topical steroids or specific allergen immunotherapy.
Rak S; Heinrich C; Scheynius A
Allergy; 2005 May; 60(5):643-9. PubMed ID: 15813810
[TBL] [Abstract][Full Text] [Related]
36. Long-term efficacy of preseasonal grass pollen immunotherapy in children.
Eng PA; Reinhold M; Gnehm HP
Allergy; 2002 Apr; 57(4):306-12. PubMed ID: 11906360
[TBL] [Abstract][Full Text] [Related]
37. Characterisation of CD154+ T cells following ex vivo birch allergen stimulation defines a close relationship between T cell subsets in healthy volunteers.
Smith KA; Gray NJ; Cheek E; Saleh F; Lavender J; Frew AJ; Kern F; Tarzi MD
BMC Immunol; 2013 Mar; 14():14. PubMed ID: 23521868
[TBL] [Abstract][Full Text] [Related]
38. Circulating eosinophil/basophil progenitors and nasal mucosal cytokines in seasonal allergic rhinitis.
Linden M; Svensson C; Andersson M; Greiff L; Andersson E; Denburg JA; Persson CG
Allergy; 1999 Mar; 54(3):212-9. PubMed ID: 10321556
[TBL] [Abstract][Full Text] [Related]
39. Oral exposure to Mal d 1 affects the immune response in patients with birch pollen allergy.
Geroldinger-Simic M; Kinaciyan T; Nagl B; Baumgartner-Durchschlag U; Huber H; Ebner C; Lidholm J; Bartel D; Vieths S; Jahn-Schmid B; Bohle B
J Allergy Clin Immunol; 2013 Jan; 131(1):94-102. PubMed ID: 22921871
[TBL] [Abstract][Full Text] [Related]
40. Birch pollen-specific subcutaneous immunotherapy reduces ILC2 frequency but does not suppress IL-33 in mice.
van Rijt LS; Logiantara A; Canbaz D; van Ree R
Clin Exp Allergy; 2018 Nov; 48(11):1402-1411. PubMed ID: 30126007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]